The Japanese government on March 7 announced new NHI prices for the FY2025 drug price revision, effective April 1. With…
BUSINESS
Daiichi Sankyo Breaks 1 Trillion Mark in FY2021 Sales on Bullish Enhertu, Lixiana
Daiichi Sankyo saw its group revenue reach 1 trillion yen in FY2021 as global sales of its cancer drug Enhertu (trastuzumab deruxtecan) more than doubled from the prior year and its top-selling product Lixiana (edoxaban) expanded market shares. In the…
To read the full story
Related Article
- Daiichi Sankyo Ups Outlook on Earnings Growth Driven by Enhertu
November 1, 2024
- Daiichi Sankyo’s Q1 Sales Grow 24% as Mainstays Fare Well
August 1, 2024
- Daiichi Sankyo Ups FY2025 Sales Goal to 2.1 Trillion Yen on Bullish Cancer Biz
April 26, 2024
- Daiichi Sankyo Ups Full-Year Outlook on Growth of Flu, COVID Products
February 1, 2024
- Daiichi Sankyo’s H1 Sales Jump 19.5% on Robust Global Products
November 1, 2023
- Daiichi Sankyo Enjoys Rosy Q1 Earnings on Strong Mainstays
August 1, 2023
- Daiichi Sankyo on Path to Net 2 Trillion Yen in Sales by FY2025 on Robust Core Products
April 28, 2023
- Daiichi Sankyo’s Revenue Up 16.9% in April-December on Buoyant Mainstays
February 1, 2023
- Daiichi Sankyo Nets Double-Digit Rise in H1 Sales as Major Products Fare Well
November 1, 2022
- Daiichi Sankyo Q1 Sales Rise 6.2% on Robust Enhertu Performance, Weaker Yen
August 1, 2022
- Daiichi Sankyo’s Revenue Rises 9.8% in April-December on Upbeat Mainstays
February 1, 2022
- Daiichi Sankyo’s 1st Half Operating Profit Jumps 44.9% Thanks to Lixiana, Enhertu
November 1, 2021
- Daiichi Sankyo’s Q1 Sales Surge on Upbeat Global Brands
August 2, 2021
- Daiichi Sankyo Sales Slip in FY2020 as Price Cuts, Deal Termination Weigh
April 28, 2021
- Daiichi Sankyo’s Revenue Down 2.4% in April-December as Mainstays Flounder at Home
February 1, 2021
- Daiichi Sankyo’s 6-Month Operating Profit Falls 32% on Higher SGA Costs for Enhertu, ADC R&D Spending
November 2, 2020
- Daiichi Sankyo Sales Skid 4.9% on Coronavirus, Price Cuts; Enhertu, Edoxaban Upbeat
August 3, 2020
BUSINESS
- Kyushu University Offshoot Eyes US Nod for Repositioned ROP Drug Candidate
March 27, 2025
- Mochida Files Actemra Biosimilar in Japan
March 27, 2025
- J&J Submits Information Disclosure Requests to Japan Govt over Off-Year Revision
March 26, 2025
- Eisai Eyes Up to 280 Billion Yen Sales for Leqembi in FY2027: CEO
March 26, 2025
- Kaken Snags Japan Rights to Alumis’ Dermatology Asset
March 26, 2025
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…